Results 71 to 80 of about 60,343,578 (236)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Topic-specific living databases of clinical trials: A scoping review of public databases

INTRODUCTION Conducting systematic reviews of clinical trials is time-consuming and resource-intensive. One potential solution is to design databases that are continuously and automatically populated with clinical trial data from harmonised and ...
Hirt, Julian, Janiaud, Perrine, Hemkens, Lars G., Boesen, Kim   +3 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Short-interval observational data to inform clinical trial design in Huntington's disease. [PDF]

, 2015
OBJECTIVES: To evaluate candidate outcomes for disease-modifying trials in Huntington's disease (HD) over 6-month, 9-month and 15-month intervals, across multiple domains.
Roos, Raymund AC, Cole, James H, Sprengelmeyer, R, Cole, JH, Mueller, H.P., Malone, IB, Hobbs, Nicola Z., Durr, Alexandra, Johnson, H., Mueller, Hans-Peter, Roos, R.A.C., Scahill, R.I., Sprengelmeyer, Reiner, Haider, Salman, Frost, C, Hobbs, Nicola Z, Hobbs, N.Z., Farmer, RE, Farmer, R.E., Tabrizi, S.J., Cole, James H.; id_orcid, Durr, A, Tabrizi, SJ, Johnson, H, Sussmuth, S.D., Tabrizi, Sarah J., Farmer, Ruth E, Rees, Elin M, Scahill, Rachael I, Hobbs, NZ, Haider, S., Frost, Chris, Farmer, Ruth E., Mueller, Hans Peter, Landwehrmeyer, B., Cole, James H., Sprengelmeyer, R., Sussmuth, Sigurd D., Malone, Ian B, Malone, I.B., Landwehrmeyer, B, Durr, A., Rees, Elin M., Roos, RA, Scahill, Rachael I., Malone, Ian B., Rees, EM, Landwehrmeyer, Bernhard, Tabrizi, Sarah J, Frost, C., Sussmuth, Sigurd D, Mueller, HP, Scahill, RI, Sussmuth, SD, Cole, J.H., Roos, Raymund A.C., Sprengelmeyer, Reiner Heinrich, Haider, S, Johnson, Hans, Rees, E.M.   +59 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge [PDF]

Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework which reproduces incentives for selective reporting and yields three ...
Nicolás Porteiro, Paula González, Matthias Dahm   +2 more
core  

Planning multi-arm screening studies within the context of a drug development programme [PDF]

, 2013
Screening trials are small trials used to decide whether an intervention is sufficiently promising to warrant a large confirmatory trial. Previous literature examined the situation where treatments are tested sequentially until one is considered ...
Wason JMS, Wason, James M. S., Jaki T, Wason, James, Jaki, Thomas, Stallard, Nigel, Thomas Jaki, Nigel Stallard, Stallard N, James M. S. Wason   +9 more
core   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression [PDF]

, 2012
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
Berger Michael, Dittmann, Sandra, Riedel Michael, Sophia, Frangou, Emanuel Severus, Bauer Michael, Severus, Emanuel, Pfennig Andrea, Florian Seemüller, Sophia Frangou, Michael, Bauer, Michael Bauer, Michael Riedel, Berger, Michael, Michael, Obermeier, Andrea, Pfennig, Michael Obermeier, Obermeier Michael, Seemüller Florian, Andrea Pfennig, Michael Berger, Hans-Jürgen, Möller, Dittmann Sandra, Michael, Riedel, Severus Emanuel, Frangou Sophia, Seemüller, Florian, Möller Hans-Jürgen, Sandra Dittmann, Hans-Jürgen Möller   +29 more
core   +2 more sources